^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    XPO1 inhibitor

    Related drugs:
    3d
    Clinical Observation and Research on the Treatment of Newly Diagnosed Diffuse Large B-cell Lymphoma with TP53 Mutation/Deletion Using Selinexor Combined with Immunochemotherapy (ChiCTR2500112284)
    P=N/A, N=40, Not yet recruiting, Department of Hematology, Fifth Medical Center of the PLA General Hospital; Fifth Medical Center of the PLA General Hospital
    New trial
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation
    |
    Xpovio (selinexor)
    5d
    Selinexor and Pembrolizumab for the Treatment of Cisplatin-Ineligible or Cisplatin-Refractory Locally Advanced or Metastatic Urothelial Carcinoma (clinicaltrials.gov)
    P1/2, N=4, Terminated, Mamta Parikh | N=12 --> 4 | Recruiting --> Terminated; Poor accrual.
    Enrollment change • Trial termination
    |
    PD-L1 (Programmed death ligand 1) • CD4 (CD4 Molecule)
    |
    Keytruda (pembrolizumab) • Xpovio (selinexor)
    7d
    Golidocitinib Combined With Selinexor for CAEBVD (clinicaltrials.gov)
    P2/3, N=28, Recruiting, Beijing Friendship Hospital
    New P2/3 trial
    |
    Xpovio (selinexor) • golidocitinib (DZD4205)
    8d
    SELCLAX: Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia (clinicaltrials.gov)
    P1, N=37, Active, not recruiting, St. Jude Children's Research Hospital | Trial completion date: Feb 2026 --> Sep 2027
    Trial completion date
    |
    Venclexta (venetoclax) • cytarabine • Xpovio (selinexor) • methotrexate • fludarabine IV • Neupogen (filgrastim)
    8d
    Dual epigenetic and nuclear export inhibition by chidamide and selinexor in high grade B-cell lymphomas via survivin and PI3K/AKT inhibition. (PubMed, Clin Epigenetics)
    Our preclinical data highlighted the potential synergistic efficacy of chidamide and selinexor in targeting HGBL-DHL, providing a rationale for further clinical investigation of this therapeutic combination for the treatment of this refractory disease.
    Journal
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6) • BCL2L1 (BCL2-like 1) • BIRC5 (Baculoviral IAP repeat containing 5) • CCNA2 (Cyclin A2) • ANXA5 (Annexin A5) • HDAC3 (Histone Deacetylase 3)
    |
    Xpovio (selinexor) • Epidaza (chidamide)
    11d
    Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma (clinicaltrials.gov)
    P1, N=11, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jul 2026 --> Jul 2028
    Trial completion date
    |
    temozolomide • Xpovio (selinexor) • loperamide
    13d
    Therapeutic Potential of Exportin 1 and Aurora Kinase A Inhibition in Multiple Myeloma Cells. (PubMed, Hematol Rep)
    Treatment of MM cells with the selective AURKA inhibitor LY3295668 induced dose-dependent cytotoxicity, caspase-3/7 activation, and cellular senescence. These findings underscore AURKA expression as a prognostic marker in plasma cell disorders and support the therapeutic potential of combining AURKA inhibition with selinexor for bortezomib-resistant MM and PCL. To explore biomarker-driven strategies for optimizing therapeutic outcomes, future studies are warranted.
    Journal • IO biomarker
    |
    AURKA (Aurora kinase A) • XPO1 (Exportin 1) • CASP3 (Caspase 3) • CASP7 (Caspase 7)
    |
    bortezomib • Xpovio (selinexor) • LY3295668
    14d
    Gemcitabine plus selinexor in selective advanced sarcomas: a phase I of the Spanish group for research on sarcoma study. (PubMed, Nat Commun)
    A phase II is currently exploring this combination in leiomyosarcoma and malignant peripheral nerve sheath tumors. Trial registration: NCT04595994.
    P1 data • Journal
    |
    XPO1 (Exportin 1)
    |
    gemcitabine • Xpovio (selinexor)
    20d
    Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma (clinicaltrials.gov)
    P2, N=129, Active, not recruiting, Canadian Cancer Trials Group | Trial primary completion date: Dec 2025 --> Mar 2026
    Trial primary completion date
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    cisplatin • Imbruvica (ibrutinib) • gemcitabine • Rituxan (rituximab) • cyclophosphamide • etoposide IV • Xpovio (selinexor) • dexamethasone • mesna
    20d
    SEATTLE: Selinexor (Nexpovio®) (SVd) in Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov)
    P=N/A, N=75, Active, not recruiting, iOMEDICO AG | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    bortezomib • Xpovio (selinexor) • dexamethasone
    26d
    GEMS-001: A Study of Drug Therapies for Salivary Gland Cancers Based on Testing of Genes (clinicaltrials.gov)
    P=N/A, N=114, Completed, University Health Network, Toronto | Active, not recruiting --> Completed
    Trial completion
    |
    Xpovio (selinexor)
    27d
    Synergistic effects of XPO1 inhibitors combined with CD19 CAR-T cells in TP53-mutated DLBCL. (PubMed, Tumori)
    The XPO1 inhibitor KPT-330 exerts anti-cancer effects through stabilizing p53 and inhibiting the PI3K-AKT pathway, providing a molecular basis for DLBCL treatment. We may provide a potential promising combination therapy for the treatment of DLBCL with p53 mutations.
    Journal • IO biomarker
    |
    TP53 (Tumor protein P53) • IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • IL2 (Interleukin 2)
    |
    TP53 mutation
    |
    Xpovio (selinexor)